JP2023041741A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023041741A5 JP2023041741A5 JP2023006500A JP2023006500A JP2023041741A5 JP 2023041741 A5 JP2023041741 A5 JP 2023041741A5 JP 2023006500 A JP2023006500 A JP 2023006500A JP 2023006500 A JP2023006500 A JP 2023006500A JP 2023041741 A5 JP2023041741 A5 JP 2023041741A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- sample
- treatment
- fragments
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011282 treatment Methods 0.000 claims 34
- 239000012634 fragment Substances 0.000 claims 26
- 210000001124 body fluid Anatomy 0.000 claims 23
- 239000010839 body fluid Substances 0.000 claims 23
- 238000000034 method Methods 0.000 claims 23
- 238000003745 diagnosis Methods 0.000 claims 11
- 230000000977 initiatory effect Effects 0.000 claims 10
- 208000035473 Communicable disease Diseases 0.000 claims 7
- 208000015181 infectious disease Diseases 0.000 claims 7
- 206010040047 Sepsis Diseases 0.000 claims 6
- 238000003018 immunoassay Methods 0.000 claims 6
- 239000003242 anti bacterial agent Substances 0.000 claims 5
- 229940088710 antibiotic agent Drugs 0.000 claims 5
- 206010053159 Organ failure Diseases 0.000 claims 3
- 206010040070 Septic Shock Diseases 0.000 claims 3
- 230000003115 biocidal effect Effects 0.000 claims 3
- 230000036303 septic shock Effects 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000005399 mechanical ventilation Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 102000004379 Adrenomedullin Human genes 0.000 claims 1
- 101800004616 Adrenomedullin Proteins 0.000 claims 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 claims 1
- 102400001018 Proadrenomedullin N-20 terminal peptide Human genes 0.000 claims 1
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 claims 1
- 108010056009 adrenotensin Proteins 0.000 claims 1
- 229940124572 antihypotensive agent Drugs 0.000 claims 1
- 238000007599 discharging Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 238000012959 renal replacement therapy Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 239000005526 vasoconstrictor agent Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17190912.0 | 2017-09-13 | ||
| EP17190912 | 2017-09-13 | ||
| PCT/EP2018/074722 WO2019053115A1 (en) | 2017-09-13 | 2018-09-13 | USE OF PROADM AS A THERAPEUTIC SURVEILLANCE MARKER FOR CRITICALLY PHASE PATIENTS |
| JP2020515677A JP7329503B2 (ja) | 2017-09-13 | 2018-09-13 | 重篤患者用の療法モニタリングマーカーとしてのｐｒｏ－ａｄｍ |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515677A Division JP7329503B2 (ja) | 2017-09-13 | 2018-09-13 | 重篤患者用の療法モニタリングマーカーとしてのｐｒｏ－ａｄｍ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023041741A JP2023041741A (ja) | 2023-03-24 |
| JP2023041741A5 true JP2023041741A5 (https=) | 2023-10-23 |
| JP7544879B2 JP7544879B2 (ja) | 2024-09-03 |
Family
ID=59887050
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515677A Active JP7329503B2 (ja) | 2017-09-13 | 2018-09-13 | 重篤患者用の療法モニタリングマーカーとしてのｐｒｏ－ａｄｍ |
| JP2020515760A Active JP7366007B2 (ja) | 2017-09-13 | 2018-09-13 | プロアドレノメジュリンに基づく輸液療法のガイダンスのための方法 |
| JP2023006500A Active JP7544879B2 (ja) | 2017-09-13 | 2023-01-19 | 重篤患者用の療法モニタリングマーカーとしてのｐｒｏ－ａｄｍ |
| JP2023175415A Abandoned JP2023181226A (ja) | 2017-09-13 | 2023-10-10 | プロアドレノメジュリンに基づく輸液療法のガイダンスのための方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515677A Active JP7329503B2 (ja) | 2017-09-13 | 2018-09-13 | 重篤患者用の療法モニタリングマーカーとしてのｐｒｏ－ａｄｍ |
| JP2020515760A Active JP7366007B2 (ja) | 2017-09-13 | 2018-09-13 | プロアドレノメジュリンに基づく輸液療法のガイダンスのための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023175415A Abandoned JP2023181226A (ja) | 2017-09-13 | 2023-10-10 | プロアドレノメジュリンに基づく輸液療法のガイダンスのための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20200300864A1 (https=) |
| EP (2) | EP3682245A1 (https=) |
| JP (4) | JP7329503B2 (https=) |
| CN (2) | CN111065927B (https=) |
| BR (1) | BR112020004138A2 (https=) |
| CA (1) | CA3075440A1 (https=) |
| WO (2) | WO2019053116A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026013199A1 (en) | 2024-07-12 | 2026-01-15 | Cezanne S.A.S. | Clinical immunoassay with early signal measurement |
| CN118976116B (zh) * | 2024-10-22 | 2025-01-24 | 四川大学华西医院 | 琥珀酰明胶在制备腹膜透析液中的用途以及一种含琥珀酰明胶、枸橼酸钠的腹膜透析液 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2570703B1 (fr) | 1984-09-26 | 1988-07-08 | Commissariat Energie Atomique | Complexes macropolycycliques de terres rares et application a titre de marqueurs fluorescents |
| US4882733A (en) | 1987-03-13 | 1989-11-21 | Ford Aerospace Corporation | Method and apparatus for combining encoding and modulation |
| FR2664699B1 (fr) | 1990-07-13 | 1995-08-18 | Cis Bio Int | Procede d'amplification du signal d'emission d'un compose luminescent. |
| DE69602756T2 (de) | 1995-08-18 | 2000-02-10 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville | Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie |
| KR100425525B1 (ko) | 2000-11-21 | 2004-03-30 | 재단법인서울대학교산학협력재단 | 조산과 태아감염 및 태아손상을 산전 진단하기 위한진단시약 및 진단키트 |
| US6864237B2 (en) * | 2002-05-17 | 2005-03-08 | Ping Wang | Treatment of shock using adrenomedullin and adrenomedullin binding protein-1 |
| DE10316583A1 (de) | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
| CN101208602A (zh) * | 2005-04-15 | 2008-06-25 | 贝克顿迪金森公司 | 脓毒症的诊断 |
| DE102006034142A1 (de) * | 2006-07-24 | 2008-01-31 | B.R.A.H.M.S. Aktiengesellschaft | Verfahren zur Steuerung der Therapie von Patienten mit Herzinsuffizienz anhand der vitro Bestimmung von Schwellenwerten von vasoaktiven Peptiden |
| US9012151B2 (en) * | 2006-11-09 | 2015-04-21 | B.R.A.H.M.S. Gmbh | Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin |
| DE102006060112A1 (de) | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM |
| US8298774B2 (en) | 2007-03-12 | 2012-10-30 | Biomedica Medizinprodukte Gmbh & Co Kg | Diagnosis of septic complications |
| PL2185937T5 (pl) | 2007-09-07 | 2014-12-31 | Univ Zuerich | Sposób wykrywania posocznicy u ludzi |
| ES2486268T3 (es) | 2007-11-16 | 2014-08-18 | Biocartis Nv | Biomarcadores y procedimientos de diagnóstico, predicción y/o pronóstico de septicemia y usos de los mismos |
| JP5989965B2 (ja) * | 2008-01-08 | 2016-09-07 | メルク シャープ エンド ドーム リミテッド | ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩 |
| EP2131200A1 (en) * | 2008-06-04 | 2009-12-09 | BRAHMS Aktiengesellschaft | A marker for graft failure and mortality |
| US9229013B2 (en) | 2009-05-05 | 2016-01-05 | B.R.A.H.M.S Gmbh | Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction |
| JP5702371B2 (ja) * | 2009-05-27 | 2015-04-15 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｍｕｃ１のアンタゴニストを使用した、炎症の阻害 |
| EP2438447B1 (en) | 2009-06-05 | 2015-02-18 | B.R.A.H.M.S GmbH | Detection of bacterial infections in subjects suffering from dyspnea. |
| US8383332B2 (en) | 2009-10-13 | 2013-02-26 | B.R.A.H.M.S. Gmbh | Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with acute stroke or transient ischemic attack |
| EP2545379B1 (en) | 2010-03-08 | 2015-09-30 | B.R.A.H.M.S GmbH | Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with non-specific complaints |
| WO2012059477A1 (en) | 2010-11-01 | 2012-05-10 | B.R.A.H.M.S Gmbh | Prognosis and risk assessment of patients with non-specific complaints |
| SG11201402362VA (en) * | 2011-11-16 | 2014-06-27 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
| CA2856150A1 (en) * | 2011-11-16 | 2013-05-23 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease |
| US11067586B2 (en) * | 2011-11-16 | 2021-07-20 | Sphingotec Gmbh | Adrenomedullin assays and methods for determining mature adrenomedullin |
| DK2780717T3 (en) * | 2011-11-16 | 2017-02-13 | Sphingotec Gmbh | ADRENOMEDULLINASSAYS AND METHODS FOR DETERMINING MODERN ADRENOMEDULLIN |
| US10935548B2 (en) | 2011-12-08 | 2021-03-02 | Astute Medical, Inc. | Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2 |
| EP2637023A1 (en) * | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
| EP2976646B1 (en) * | 2013-03-20 | 2020-08-19 | sphingotec GmbH | Adrenomedullin to guide therapy of blood pressure decline |
| US9597730B2 (en) * | 2013-04-19 | 2017-03-21 | United Technologies Corporation | Build plate and apparatus for additive manufacturing |
| US20180348235A1 (en) | 2015-11-27 | 2018-12-06 | B.R.A.H.M.S Gmbh | MR-proADM as marker for the extracellular volume status of a subject |
| EP4231018A3 (en) | 2016-07-08 | 2023-11-15 | SphingoTec GmbH | Adrenomedullin for assessing congestion in a subject with acute heart failure |
| CA3033094A1 (en) | 2016-08-09 | 2018-02-15 | B.R.A.H.M.S Gmbh | Histones and/or proadm as markers indicating an adverse event |
-
2018
- 2018-09-13 WO PCT/EP2018/074723 patent/WO2019053116A1/en not_active Ceased
- 2018-09-13 BR BR112020004138-6A patent/BR112020004138A2/pt unknown
- 2018-09-13 WO PCT/EP2018/074722 patent/WO2019053115A1/en not_active Ceased
- 2018-09-13 JP JP2020515677A patent/JP7329503B2/ja active Active
- 2018-09-13 JP JP2020515760A patent/JP7366007B2/ja active Active
- 2018-09-13 EP EP18765656.6A patent/EP3682245A1/en active Pending
- 2018-09-13 US US16/646,637 patent/US20200300864A1/en active Pending
- 2018-09-13 CN CN201880059136.6A patent/CN111065927B/zh active Active
- 2018-09-13 US US16/646,639 patent/US12517138B2/en active Active
- 2018-09-13 EP EP18765657.4A patent/EP3682246A1/en active Pending
- 2018-09-13 CA CA3075440A patent/CA3075440A1/en active Pending
- 2018-09-13 CN CN201880059366.2A patent/CN111094986B/zh active Active
-
2023
- 2023-01-19 JP JP2023006500A patent/JP7544879B2/ja active Active
- 2023-10-10 JP JP2023175415A patent/JP2023181226A/ja not_active Abandoned
-
2025
- 2025-01-17 US US19/027,967 patent/US20250189539A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Viguier et al. | High frequency of cholestasis in generalized pustular psoriasis: evidence for neutrophilic involvement of the biliary tract | |
| JP2023041741A5 (https=) | ||
| JP2021507236A (ja) | プロカルシトニンと中間領域プロアドレノメデュリンを使用したリスク評価と患者管理のためのワークフロー | |
| JP3095784B2 (ja) | 炎症プロセスの病因を決定するための診断方法 | |
| EP4573371A2 (en) | Diagnosis and treatment of acute kidney injury | |
| Yamazoe et al. | Anti-mda5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressing interstitial lung disease successfully treated by initiation of combined immunosuppressive therapy plus plasma exchange and subsequently switching tacrolimus to tofacitinib | |
| Gao et al. | Clinical analysis of AN69ST membrane continuous venous hemofiltration in the treatment of severe sepsis | |
| WO2009009907A1 (en) | Use of vasopressin-receptor agonists for the treatment of septic shock | |
| JP2020533604A5 (https=) | ||
| CN120882881A (zh) | 溃疡性结肠炎的基因调控及其用途 | |
| Cikes et al. | Rationale, design and baseline characteristics of the multicenter, randomized, open-label, parallel group, study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients (ENVAD-HF) | |
| RU2333497C1 (ru) | Способ прогнозирования хронической почечной недостаточности у больных с посткапилляротоксическим гломерулонефритом | |
| EP2350654A2 (en) | Methods of using sdf-1 (cxcl12) as a diagnostic and mesenchymal stem cell (multipotent stromal cell)-specific therapeutic biomarker for the treatment of kidney injury and other major organs | |
| Nikolova et al. | Acute Kidney Injury and Acute Renal Failure in Coronaviral Infection | |
| Hamouda et al. | POS-170 ACUTE INTERSTITIAL NEPHRITIS: A RETROSPECTIVE STUDY OF 60 PATIENTS | |
| SU1545159A1 (ru) | Способ прогнозировани обострени подагрического артрита | |
| Nugent et al. | Periodic polyserositis (periodic disease) | |
| CN114107484B (zh) | 溃疡性结肠炎标志基因及其应用 | |
| Japar et al. | 19 Prevalence and Characteristics of Patients with Intradialytic Hypertension in Indonesia | |
| CN113376386B (zh) | 一种病毒性肺炎的标志物及其应用 | |
| DONG et al. | POS-141 Comparison of Clinical Efficacy of Centrifugal-Membranous Double Filtration Plasmapheresis and Membranous Double Filtration Plasmapheresis on Severe Lupus Nephritis | |
| CN121380321A (zh) | 一种定量检测心力衰竭的生物标志物及其应用 | |
| Arroyo et al. | PRIMER | |
| Kadori et al. | Protocol-defined Systemic Steroid Dose-induced Bradycardia in Multisystem Inflammatory Syndrome in Children: A Case Report | |
| Hong et al. | WCN25-377 Metabolic assessment in non-dialysis patients with chronic kidney disease |